Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 3.210 | 3.210 | 0.000 |
Stocks | 96.790 | 96.790 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 29.119 | 23.931 |
Price to Book | 10.284 | 4.517 |
Price to Sales | 5.423 | 3.291 |
Price to Cash Flow | 22.968 | 15.856 |
Dividend Yield | 1.382 | 1.239 |
5 Years Earnings Growth | 9.992 | 12.450 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 31.950 | 16.432 |
Consumer Defensive | 31.600 | 7.948 |
Technology | 12.830 | 26.715 |
Financial Services | 9.210 | 13.504 |
Consumer Cyclical | 8.150 | 12.466 |
Industrials | 6.260 | 11.862 |
Number of long holdings: 25
Number of short holdings: 0
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
L'Oreal | FR0000120321 | 5.74 | 452.10 | +1.66% | |
Intuit | US4612021034 | 5.08 | 576.44 | +2.39% | |
Waters | US9418481035 | 4.88 | 308.90 | +0.42% | |
Microsoft | US5949181045 | 4.79 | 415.13 | +0.23% | |
Visa A | US92826C8394 | 4.58 | 272.46 | +0.43% | |
Novo Nordisk A/S Class B | DK0060534915 | 4.52 | - | - | |
Stryker | US8636671013 | 4.48 | 341.09 | +0.17% | |
Church&Dwight | US1713401024 | 4.48 | 107.08 | +2.61% | |
PayPal | US70450Y1038 | 4.33 | 62.99 | +0.78% | |
J&J | US4781601046 | 4.33 | 146.67 | +0.96% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fundsmith Equity I Acc | 15.14B | 7.14 | 5.85 | 15.68 | ||
Fundsmith Equity I Inc | 4.54B | 7.14 | 5.85 | 15.68 | ||
Fundsmith Equity R Acc | 595.77M | 6.92 | 5.21 | 14.98 | ||
Fundsmith Equity R Inc | 17.28M | 6.92 | 5.21 | 14.97 | ||
Fundsmith Equity T Acc | 4.11B | 7.10 | 5.74 | 15.57 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review